Changsong Qi

3.3k total citations · 1 hit paper
71 papers, 1.2k citations indexed

About

Changsong Qi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Changsong Qi has authored 71 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Changsong Qi's work include Cancer Immunotherapy and Biomarkers (24 papers), Gastric Cancer Management and Outcomes (20 papers) and Colorectal Cancer Treatments and Studies (14 papers). Changsong Qi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Gastric Cancer Management and Outcomes (20 papers) and Colorectal Cancer Treatments and Studies (14 papers). Changsong Qi collaborates with scholars based in China, Ethiopia and United States. Changsong Qi's co-authors include Lin Shen, Lin Shen, Jifang Gong, Jian Li, Zhi Peng, Xiaotian Zhang, Yakun Wang, Qi Zhang, Zhening Zhang and Xicheng Wang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Changsong Qi

65 papers receiving 1.2k citations

Hit Papers

Claudin 18.2 as a novel therapeutic target 2024 2026 2025 2024 20 40 60
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Claudin 18.2 as a novel therapeutic target
    2024 73 citations Izuma Nakayama, Changsong Qi et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Changsong Qi China 21 688 408 272 226 204 71 1.2k
Jiachen Xu China 17 562 0.8× 357 0.9× 256 0.9× 141 0.6× 208 1.0× 51 1.0k
Yifeng Zou China 22 610 0.9× 176 0.4× 408 1.5× 261 1.2× 188 0.9× 67 1.2k
Shisuo Du China 18 471 0.7× 241 0.6× 412 1.5× 127 0.6× 291 1.4× 77 1.2k
Jieer Ying China 18 850 1.2× 532 1.3× 324 1.2× 430 1.9× 175 0.9× 95 1.7k
Enzo Maria Ruggeri Italy 22 681 1.0× 535 1.3× 274 1.0× 354 1.6× 93 0.5× 103 1.4k
Ηλίας Κοττέας Greece 18 570 0.8× 330 0.8× 319 1.2× 74 0.3× 119 0.6× 76 1.1k
Yoon Dae Han South Korea 19 774 1.1× 231 0.6× 201 0.7× 418 1.8× 240 1.2× 90 1.2k
Shigenori Homma Japan 20 786 1.1× 503 1.2× 237 0.9× 467 2.1× 348 1.7× 112 1.5k

Countries citing papers authored by Changsong Qi

Since Specialization
Citations

This map shows the geographic impact of Changsong Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changsong Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changsong Qi more than expected).

Fields of papers citing papers by Changsong Qi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changsong Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changsong Qi. The network helps show where Changsong Qi may publish in the future.

Co-authorship network of co-authors of Changsong Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Changsong Qi. A scholar is included among the top collaborators of Changsong Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changsong Qi. Changsong Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qi, Changsong, Lin Shen, Thierry André, et al.. (2025). Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal of Cancer. 220. 115338–115338. 5 indexed citations
2.
3.
Qi, Changsong, Chang Liu, Xiaofei Wei, et al.. (2024). Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. Journal for ImmunoTherapy of Cancer. 12(10). e009960–e009960. 5 indexed citations
4.
Jiang, Licui, Fengtao You, Changsong Qi, et al.. (2024). B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors. Cancer Research. 84(23). 4066–4080. 7 indexed citations
5.
6.
Qi, Changsong, Rui Guo, Yan Chen, et al.. (2024). 68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients. Journal of Nuclear Medicine. 65(6). 856–863. 13 indexed citations
7.
Nakayama, Izuma, Changsong Qi, Yang Chen, et al.. (2024). Claudin 18.2 as a novel therapeutic target. Nature Reviews Clinical Oncology. 21(5). 354–369. 73 indexed citations breakdown →
8.
Qi, Changsong, Xiaoyi Chong, Mingyang Ma, et al.. (2024). Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study. Chinese Journal of Cancer Research. 36(1). 78–89. 15 indexed citations
9.
Qi, Changsong, Liangzheng Chang, Jiyao Li, et al.. (2023). 1018O Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer. Annals of Oncology. 34. S620–S620. 2 indexed citations
10.
Zhang, Zhening, Yiyi Yu, Tong Xie, et al.. (2023). Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET‐amplified gastric cancer. Cancer Medicine. 12(19). 19583–19594. 1 indexed citations
11.
Wang, Shujing, Changsong Qi, Jin Ding, et al.. (2023). First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2802–2817. 19 indexed citations
12.
Qi, Changsong, Yuezong Bai, Hui Chen, et al.. (2023). China special issue on gastrointestinal tumors—NTRK fusion in a large real‐world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment. International Journal of Cancer. 153(11). 1916–1927. 2 indexed citations
13.
Jia, Keren, Yang Chen, Yu Sun, et al.. (2022). Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Medicine. 20(1). 223–223. 59 indexed citations
14.
15.
Zhang, Zhening, Siyuan Cheng, Changsong Qi, et al.. (2021). Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report. Annals of Palliative Medicine. 11(2). 818–826. 5 indexed citations
16.
Zong, Yuan, Changsong Qi, Zhi Peng, Lin Shen, & Jun Zhou. (2020). Patients With Acinar Cell Carcinoma of the Pancreas After 2005. Pancreas. 49(6). 781–787. 15 indexed citations
17.
Zhou, Nina, Chang Liu, Xiaoyi Guo, et al.. (2020). Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. European Journal of Nuclear Medicine and Molecular Imaging. 48(1). 161–175. 31 indexed citations
18.
Zhang, Zhening, et al.. (2020). Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives. Chinese Journal of Cancer Research. 32(3). 287–302. 25 indexed citations
19.
Wang, Xiaojuan, William Ka Kei Wu, Jing Gao, et al.. (2019). Autophagy inhibition enhances PD-L1 expression in gastric cancer. Journal of Experimental & Clinical Cancer Research. 38(1). 140–140. 145 indexed citations
20.
Hu, Yanting, Changsong Qi, Xiang Liu, et al.. (2019). Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. Cancer Letters. 457. 142–150. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiachen Xu Breakdown of academic impact, for papers by Yifeng Zou Breakdown of academic impact, for papers by Shisuo Du Breakdown of academic impact, for papers by Jieer Ying Breakdown of academic impact, for papers by Enzo Maria Ruggeri Breakdown of academic impact, for papers by Ηλίας Κοττέας Breakdown of academic impact, for papers by Yoon Dae Han Breakdown of academic impact, for papers by Shigenori Homma
Rankless by CCL
2026